JPH11513023A - 2−オキサゾリジノン誘導体のワンポット合成 - Google Patents
2−オキサゾリジノン誘導体のワンポット合成Info
- Publication number
- JPH11513023A JPH11513023A JP9508226A JP50822697A JPH11513023A JP H11513023 A JPH11513023 A JP H11513023A JP 9508226 A JP9508226 A JP 9508226A JP 50822697 A JP50822697 A JP 50822697A JP H11513023 A JPH11513023 A JP H11513023A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- methyl
- oxazolidinone
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000005580 one pot reaction Methods 0.000 title claims description 14
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 55
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 239000012954 diazonium Substances 0.000 claims abstract description 7
- 150000001989 diazonium salts Chemical class 0.000 claims abstract description 7
- 238000006641 Fischer synthesis reaction Methods 0.000 claims abstract description 6
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 claims abstract description 6
- BTHMRXRBXYHLRA-FVGYRXGTSA-N methyl (2s)-2-amino-3-(4-nitrophenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 BTHMRXRBXYHLRA-FVGYRXGTSA-N 0.000 claims abstract description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims abstract description 3
- 125000004492 methyl ester group Chemical group 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 116
- 239000000243 solution Substances 0.000 claims description 50
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 9
- NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical compound CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000012279 sodium borohydride Substances 0.000 claims description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- OSUKKPIXRGNCBB-ZDUSSCGKSA-N butyl n-[(2s)-1-(4-aminophenyl)-3-hydroxypropan-2-yl]carbamate Chemical compound CCCCOC(=O)N[C@H](CO)CC1=CC=C(N)C=C1 OSUKKPIXRGNCBB-ZDUSSCGKSA-N 0.000 claims description 5
- BXCCIZOPQQWMKN-ZDUSSCGKSA-N methyl (2s)-2-(butoxycarbonylamino)-3-(4-nitrophenyl)propanoate Chemical compound CCCCOC(=O)N[C@H](C(=O)OC)CC1=CC=C([N+]([O-])=O)C=C1 BXCCIZOPQQWMKN-ZDUSSCGKSA-N 0.000 claims description 5
- RPGKNZIGMYPYML-ZDUSSCGKSA-N methyl (2s)-3-(4-aminophenyl)-2-(butoxycarbonylamino)propanoate Chemical compound CCCCOC(=O)N[C@H](C(=O)OC)CC1=CC=C(N)C=C1 RPGKNZIGMYPYML-ZDUSSCGKSA-N 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 235000010265 sodium sulphite Nutrition 0.000 claims description 5
- WNAVSKJKDPLWBD-VIFPVBQESA-N (4s)-4-[(4-aminophenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(N)=CC=C1C[C@@H]1NC(=O)OC1 WNAVSKJKDPLWBD-VIFPVBQESA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 3
- 235000010288 sodium nitrite Nutrition 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- IMAZLPMRHTYSQZ-WWPIYYJJSA-N hydrazine (4S)-4-[(4-hydrazinylphenyl)methyl]-1,3-oxazolidin-2-one hydrochloride Chemical compound Cl.NN.C1=CC(NN)=CC=C1C[C@@H]1NC(=O)OC1 IMAZLPMRHTYSQZ-WWPIYYJJSA-N 0.000 claims description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 7
- 239000003610 charcoal Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 229910004298 SiO 2 Inorganic materials 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 3
- QKXMWBLNSPNBEY-UHFFFAOYSA-N 4,4-diethoxy-n,n-dimethylbutan-1-amine Chemical compound CCOC(OCC)CCCN(C)C QKXMWBLNSPNBEY-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- RKJYNLQSYQZGHQ-LBPRGKRZSA-N (2s)-2-(butoxycarbonylamino)-3-(4-nitrophenyl)propanoic acid Chemical compound CCCCOC(=O)N[C@H](C(O)=O)CC1=CC=C([N+]([O-])=O)C=C1 RKJYNLQSYQZGHQ-LBPRGKRZSA-N 0.000 description 1
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
- FUFUQQWIXMPZFU-VIFPVBQESA-N (s)-methyl 2-amino-3-(4-nitrophenyl)propanoate Chemical compound COC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 FUFUQQWIXMPZFU-VIFPVBQESA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(S)-4-{[3-[2-(ジメチルアミノ)エチル]-1H-インドール-5-イル]メチル}-2- オキサゾリジノンを調製するプロセスであって、以下の工程を包含するプロセス : a)炭酸ナトリウムまたは炭酸水素ナトリウムおよびn-ブチルクロロホルメー トを添加し反応させることにより、式(II)で表されるメチル4-ニトロ-(L)-フ ェニルアラニネートヒドロクロリドからカルバメートを形成し、 式(III)で表されるメチル(S)-N-ブトキシカルボニル-4-ニトロフェニルアラ ニネートを得る工程 b)式(III)の化合物を還元して、式(IV)で表されるメチル(S)-N-ブトキ シカルボニル-4-アミノフェニルアラニネートを得る工程 c)式(IV)の化合物中のメチルエステル基-CO2CH3を還元して、式(V)で表 される(S)-N-ブトキシカルボニル-4-アミノフェニルアラニノールを得る工程 d)式(V)の化合物を閉環し、式(VI)で表される(S)-4-(4-アミノベンジル) -2-オキサゾリジノンを得る工程 e)式(VI)の化合物のジアゾニウム塩を調製し、続いて還元し、式(VII)で 表されるヒドラジン(S)-4-(4-ヒドラジノベンジル)-2-オキサゾリジノンヒドロ クロリドを得る工程 f)式(VII)の化合物のフィッシャー反応により式(I)の化合物を得る工 程。 2.ワンポット手順を使用して工程a)からf)の1個以上の工程が実施される 、請求項1に記載のプロセス。 3.ワンポット手順によって工程a)からd)が実施され、続いて式(VI)の化 合物を単離し、次いで工程e)とf)とが第二のワンポット手順によって実施さ れる、請求項1または2に記載のプロセス。 4.炭酸ナトリウムを使用して、水性酢酸エチル溶媒の存在下で工程a)が実施 される、請求項1〜3のいずれか1項に記載のプロセス。 5.工程a)において炭酸ナトリウムを温度約20℃で添加し、およびN-ブチルク ロロホルメートを温度約30℃で添加する、請求項4に記載のプロセス。 6.工程b)が水素添加によって実施される、請求項1〜5のいずれか1項に記 載のプロセス。 7.工程c)の還元が水素化ホウ素ナトリウムを使用して行われる、請求項1〜 6のいずれか1項に記載のプロセス。 8.工程d)が式(V)の化合物の乾燥ブタノール溶液において実施される、請 求項1〜7のいずれか1項に記載のプロセス。 9.ナトリウムメトキシドの30%メタノール溶液を使用して、50〜120℃の範囲 の温度で閉環が実施される、請求項1〜8のいずれか1項に記載のプロセス。 10.工程e)が i)式(VI)の化合物を亜硝酸ナトリウムと反応させること、および ii)i)で生成したジアゾニウム塩を亜硫酸ナトリウムを使用して還元するこ と によって実施される、請求項1〜9のいずれか1項に記載のプロセス。 11.工程f)のフィッシャー反応が相対的に高い希釈度で実施される、請求項 1〜10のいずれか1項に記載のプロセス。 12.(S)-4-{[3-(ジメチルアミノ)エチル]-1H-インドール-5-イル]-メチル}-2- オキサゾリジノンの精製プロセスであって、以下の工程を包含するプロセス: a)酢酸エチル中のエタノールの還流混合物中に粗(S)-4-{[3-(ジメチルアミ ノ)エチル]-1H-インドール-5-イル]-メチル}-2-オキサゾリジノンを溶解し、そ してその熱溶液を濾過する工程 b)該濾過した溶液を約5℃の温度まで徐冷する工程 c)工程b)による生成物を遠心分離し、酢酸エチルで洗浄し、次いで乾燥す る工程;および d)アセトンで処理し、溶媒和した酢酸エチルを除去する工程。 13.溶媒和していない純粋な(S)-4-{[3-(ジメチルアミノエチル)-1H-インドー ル-5-イル]-メチル}-2-オキサゾリジノン。 14.式(III)の中間体 15.式(IV)の中間体 16.式(V)の中間体 17.式(VI)の中間体 18.式(III)の化合物を調製するプロセスであって、 式(II)の化合物を炭酸ナトリウムおよびn-ブチルクロロホルメートと反応させ る工程を包含するプロセス 19.式(IV)の化合物を調製するプロセスであって、 式(III)の化合物を還元する工程を包含するプロセス 20.式(V)の化合物を調製するプロセスであって、 式(IV)の化合物を還元する工程を包含するプロセス 21.式(VI)の化合物を調製するプロセスであって、 式(V)の化合物を閉環する工程を包含するプロセス 22.医薬使用のための組成物の製造における、請求項14に記載の中間体の使 用。 23.医薬使用のための組成物の製造における、請求項15に記載の中間体の使 用。 24.医薬使用のための組成物の製造における、請求項16に記載の中間体の使 用。 25.医薬使用のための組成物の製造における、請求項17に記載の中間体の使 用。 26.前記組成物が偏頭痛の治療および予防において使用される、請求項22〜 25のいずれか1項に記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9516145.1 | 1995-08-07 | ||
| GBGB9516145.1A GB9516145D0 (en) | 1995-08-07 | 1995-08-07 | Improved chemical synthesis |
| PCT/GB1996/001885 WO1997006162A1 (en) | 1995-08-07 | 1996-08-02 | One pot synthesis of 2-oxazolidinone derivatives |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001228782A Division JP3739678B2 (ja) | 1995-08-07 | 2001-07-27 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2001228781A Division JP2002037786A (ja) | 1995-08-07 | 2001-07-27 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2002086955A Division JP2002308858A (ja) | 1995-08-07 | 2002-03-26 | 2−オキサゾリジノン誘導体のワンポット合成 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11513023A true JPH11513023A (ja) | 1999-11-09 |
| JP3729503B2 JP3729503B2 (ja) | 2005-12-21 |
Family
ID=10778867
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50822697A Expired - Lifetime JP3729503B2 (ja) | 1995-08-07 | 1996-08-02 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2001228781A Withdrawn JP2002037786A (ja) | 1995-08-07 | 2001-07-27 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2001228782A Expired - Lifetime JP3739678B2 (ja) | 1995-08-07 | 2001-07-27 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2002086955A Withdrawn JP2002308858A (ja) | 1995-08-07 | 2002-03-26 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2005334990A Expired - Lifetime JP4634286B2 (ja) | 1995-08-07 | 2005-11-18 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2006152810A Withdrawn JP2006225406A (ja) | 1995-08-07 | 2006-05-31 | 2−オキサゾリジノン誘導体のワンポット合成 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001228781A Withdrawn JP2002037786A (ja) | 1995-08-07 | 2001-07-27 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2001228782A Expired - Lifetime JP3739678B2 (ja) | 1995-08-07 | 2001-07-27 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2002086955A Withdrawn JP2002308858A (ja) | 1995-08-07 | 2002-03-26 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2005334990A Expired - Lifetime JP4634286B2 (ja) | 1995-08-07 | 2005-11-18 | 2−オキサゾリジノン誘導体のワンポット合成 |
| JP2006152810A Withdrawn JP2006225406A (ja) | 1995-08-07 | 2006-05-31 | 2−オキサゾリジノン誘導体のワンポット合成 |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US6084103A (ja) |
| EP (2) | EP1227095B1 (ja) |
| JP (6) | JP3729503B2 (ja) |
| KR (1) | KR100670704B1 (ja) |
| CN (3) | CN1244579C (ja) |
| AR (2) | AR006515A1 (ja) |
| AT (2) | ATE325121T1 (ja) |
| AU (1) | AU718413B2 (ja) |
| BR (1) | BR9609830A (ja) |
| CA (2) | CA2227039C (ja) |
| CZ (2) | CZ293050B6 (ja) |
| DE (2) | DE69624825T2 (ja) |
| DK (2) | DK1227095T3 (ja) |
| ES (2) | ES2185790T3 (ja) |
| GB (1) | GB9516145D0 (ja) |
| HK (1) | HK1047094B (ja) |
| HU (1) | HU229966B1 (ja) |
| IL (4) | IL123171A (ja) |
| IN (2) | IN185148B (ja) |
| MX (1) | MX9801044A (ja) |
| MY (1) | MY117571A (ja) |
| NO (2) | NO311690B1 (ja) |
| NZ (1) | NZ315040A (ja) |
| PL (1) | PL188805B1 (ja) |
| PT (2) | PT1227095E (ja) |
| RO (2) | RO121816B1 (ja) |
| RU (1) | RU2167875C2 (ja) |
| SI (2) | SI1227095T1 (ja) |
| SK (1) | SK285052B6 (ja) |
| TR (1) | TR199800182T1 (ja) |
| TW (1) | TW358811B (ja) |
| UA (1) | UA53625C2 (ja) |
| WO (1) | WO1997006162A1 (ja) |
| ZA (1) | ZA966711B (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540613A (ja) * | 2007-10-03 | 2010-12-24 | ジェネリクス・(ユーケー)・リミテッド | ゾルミトリプタン、その塩、及びその溶媒和物の調製方法 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5851400A (en) * | 1999-07-09 | 2001-01-30 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of aniline derivatives |
| GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
| ES2204302B2 (es) | 2002-08-07 | 2005-03-01 | Laboratorios Vita, S.A. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo. |
| US20070173536A1 (en) * | 2004-02-06 | 2007-07-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of zolmitriptan |
| EP1812428A2 (en) * | 2004-11-19 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Zolmitriptan crystal forms |
| JP4935675B2 (ja) | 2005-08-25 | 2012-05-23 | 宇部興産株式会社 | 光学活性(S又はR)−α−アミノ酸及び光学活性(R又はS)−α−アミノ酸エステルの製造方法 |
| ATE510836T1 (de) * | 2006-01-19 | 2011-06-15 | Matrix Lab Ltd | Umwandlung eines aromatischen diazoniumsalzes in ein arylhydrazin |
| WO2008007390A2 (en) * | 2006-07-10 | 2008-01-17 | Natco Pharma Limited | An improved process for purification of zolmitriptan |
| WO2008018090A2 (en) * | 2006-08-09 | 2008-02-14 | Matrix Laboratories Ltd | An improved process for the preparation of zolmitriptan |
| CZ301538B6 (cs) | 2007-02-26 | 2010-04-07 | Zentiva, A. S. | Zpusob prípravy zolmitriptanu |
| CZ2007158A3 (cs) * | 2007-02-26 | 2008-10-22 | Zentiva, A. S. | Zpusob prípravy zolmitriptanu |
| CN101230047B (zh) * | 2008-02-04 | 2010-08-04 | 江苏中威药业有限公司 | 一种4-取代手性噁唑烷酮类化合物的制备方法 |
| EP2387993B1 (en) * | 2010-05-21 | 2012-11-07 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Orally disintegrating tablets of zolmitriptan and process for preparing the same |
| CN101948443B (zh) * | 2010-08-17 | 2012-08-22 | 河南师范大学 | 一种简单、高效合成4-取代噁唑烷酮衍生物的方法 |
| WO2012135615A2 (en) | 2011-03-30 | 2012-10-04 | Brown University | Enopeptins, uses thereof, and methods of synthesis thereto |
| EP2751098B1 (en) | 2011-09-02 | 2017-11-29 | Emcure Pharmaceuticals Limited | An improved process for preparation of zolmitriptan |
| CN102964270B (zh) * | 2012-11-21 | 2015-01-07 | 合肥星宇化学有限责任公司 | 一种亚硫酸钠还原重氮盐合成肼的方法 |
| CN103275075B (zh) * | 2013-06-24 | 2015-01-07 | 成都天台山制药有限公司 | 佐米曲普坦及其制备方法 |
| WO2016037072A2 (en) * | 2014-09-04 | 2016-03-10 | Brown University | Enopeptin analogas and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3879410A (en) * | 1971-02-08 | 1975-04-22 | Messrs Lab Guidotti & C S P A | 4-Aryl-4-oxazolin-2-ones exhibiting myotonic and myorelaxing activity |
| GB1478108A (en) * | 1975-10-30 | 1977-06-29 | Nippon Chemipar Co Ltd | 5-benzyl-2-oxazolidone derivatives and a process for producing the same |
| GB8724912D0 (en) * | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
| PT97888B (pt) * | 1990-06-07 | 1998-12-31 | Zeneca Ltd | Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem |
| GB9012672D0 (en) * | 1990-06-07 | 1990-08-01 | Wellcome Found | Therapeutic heterocyclic compounds |
| GB9401436D0 (en) * | 1994-01-26 | 1994-03-23 | Wellcome Found | Therapeutic heterocyclic compounds |
| GB9423682D0 (en) * | 1994-11-23 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
| US6025374A (en) * | 1994-12-06 | 2000-02-15 | Merck Sharp & Dohme, Ltd. | Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists |
-
1995
- 1995-08-07 GB GBGB9516145.1A patent/GB9516145D0/en active Pending
-
1996
- 1996-02-08 UA UA98031096A patent/UA53625C2/uk unknown
- 1996-08-02 MX MX9801044A patent/MX9801044A/es unknown
- 1996-08-02 CA CA002227039A patent/CA2227039C/en not_active Expired - Lifetime
- 1996-08-02 KR KR1019980700833A patent/KR100670704B1/ko not_active Expired - Lifetime
- 1996-08-02 RO ROA200400914A patent/RO121816B1/ro unknown
- 1996-08-02 ES ES96926465T patent/ES2185790T3/es not_active Expired - Lifetime
- 1996-08-02 CN CNB011330929A patent/CN1244579C/zh not_active Expired - Lifetime
- 1996-08-02 CA CA2572508A patent/CA2572508C/en not_active Expired - Lifetime
- 1996-08-02 EP EP02008427A patent/EP1227095B1/en not_active Expired - Lifetime
- 1996-08-02 DK DK02008427T patent/DK1227095T3/da active
- 1996-08-02 PL PL96324881A patent/PL188805B1/pl unknown
- 1996-08-02 AU AU66634/96A patent/AU718413B2/en not_active Expired
- 1996-08-02 DE DE69624825T patent/DE69624825T2/de not_active Expired - Lifetime
- 1996-08-02 PT PT02008427T patent/PT1227095E/pt unknown
- 1996-08-02 WO PCT/GB1996/001885 patent/WO1997006162A1/en not_active Ceased
- 1996-08-02 CN CN96197237A patent/CN1092657C/zh not_active Expired - Lifetime
- 1996-08-02 HU HU9900188A patent/HU229966B1/hu unknown
- 1996-08-02 DK DK96926465T patent/DK0843672T3/da active
- 1996-08-02 SK SK154-98A patent/SK285052B6/sk not_active IP Right Cessation
- 1996-08-02 BR BR9609830A patent/BR9609830A/pt not_active Application Discontinuation
- 1996-08-02 SI SI9630738T patent/SI1227095T1/sl unknown
- 1996-08-02 TR TR1998/00182T patent/TR199800182T1/xx unknown
- 1996-08-02 US US09/011,045 patent/US6084103A/en not_active Expired - Lifetime
- 1996-08-02 NZ NZ315040A patent/NZ315040A/xx not_active IP Right Cessation
- 1996-08-02 IL IL12317196A patent/IL123171A/xx not_active IP Right Cessation
- 1996-08-02 JP JP50822697A patent/JP3729503B2/ja not_active Expired - Lifetime
- 1996-08-02 DE DE69636107T patent/DE69636107T2/de not_active Expired - Lifetime
- 1996-08-02 IL IL156733A patent/IL156733A/en not_active IP Right Cessation
- 1996-08-02 AT AT02008427T patent/ATE325121T1/de active
- 1996-08-02 RO RO98-00214A patent/RO119618B1/ro unknown
- 1996-08-02 CZ CZ1998352A patent/CZ293050B6/cs not_active IP Right Cessation
- 1996-08-02 IL IL148030A patent/IL148030A/en not_active IP Right Cessation
- 1996-08-02 CZ CZ20031498A patent/CZ301603B6/cs not_active IP Right Cessation
- 1996-08-02 CN CNB01112010XA patent/CN1142904C/zh not_active Expired - Lifetime
- 1996-08-02 EP EP96926465A patent/EP0843672B1/en not_active Expired - Lifetime
- 1996-08-02 RU RU98104085/04A patent/RU2167875C2/ru active
- 1996-08-02 AT AT96926465T patent/ATE227723T1/de active
- 1996-08-02 ES ES02008427T patent/ES2261545T3/es not_active Expired - Lifetime
- 1996-08-02 PT PT96926465T patent/PT843672E/pt unknown
- 1996-08-02 SI SI9630560T patent/SI0843672T1/xx unknown
- 1996-08-06 IN IN1742DE1996 patent/IN185148B/en unknown
- 1996-08-06 MY MYPI96003220A patent/MY117571A/en unknown
- 1996-08-07 ZA ZA9606711A patent/ZA966711B/xx unknown
- 1996-08-07 AR ARP960103909A patent/AR006515A1/es active IP Right Grant
- 1996-10-01 TW TW085111923A patent/TW358811B/zh not_active IP Right Cessation
-
1998
- 1998-02-06 NO NO19980522A patent/NO311690B1/no not_active IP Right Cessation
- 1998-08-19 HK HK02108548.8A patent/HK1047094B/en not_active IP Right Cessation
-
2000
- 2000-02-02 US US09/496,409 patent/US6160123A/en not_active Expired - Lifetime
- 2000-04-25 IN IN454DE2000 patent/IN189756B/en unknown
- 2000-10-16 NO NO20005187A patent/NO311691B1/no not_active IP Right Cessation
-
2001
- 2001-07-27 JP JP2001228781A patent/JP2002037786A/ja not_active Withdrawn
- 2001-07-27 JP JP2001228782A patent/JP3739678B2/ja not_active Expired - Lifetime
-
2002
- 2002-02-06 IL IL14803002A patent/IL148030A0/xx unknown
- 2002-03-26 JP JP2002086955A patent/JP2002308858A/ja not_active Withdrawn
-
2003
- 2003-05-02 AR ARP030101543A patent/AR046236A2/es active IP Right Grant
-
2005
- 2005-11-18 JP JP2005334990A patent/JP4634286B2/ja not_active Expired - Lifetime
-
2006
- 2006-05-31 JP JP2006152810A patent/JP2006225406A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540613A (ja) * | 2007-10-03 | 2010-12-24 | ジェネリクス・(ユーケー)・リミテッド | ゾルミトリプタン、その塩、及びその溶媒和物の調製方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH11513023A (ja) | 2−オキサゾリジノン誘導体のワンポット合成 | |
| FR2600061A1 (fr) | Derives d'indole, composition pharmaceutique les contenant et procede pour leur preparation | |
| EP0385848A1 (fr) | Nouveaux dérivés benzoxazolinoniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
| JP3729504B2 (ja) | 2−オキサゾリジノン誘導体のワンポット合成 | |
| US6909005B1 (en) | One post synthesis of 2-oxazolidinone derivatives | |
| HK1009129B (en) | One pot synthesis of 2-oxazolidinone derivatives | |
| JP2001503393A (ja) | 新規ヘテロアリールオキシエチルアミン、その製造方法、その医薬としての使用及びこれを含有する医薬組成物 | |
| JP2001503392A (ja) | 新規フェノキシエチルアミン誘導体、その製造方法、医薬としてのその使用及びそれを含有する医薬組成物 | |
| JPH10120680A (ja) | 新規インドリジン化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050831 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051004 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081014 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091014 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091014 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101014 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101014 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111014 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111014 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121014 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131014 Year of fee payment: 8 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |